Laura A Cisar
Overview
Explore the profile of Laura A Cisar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
227
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
MacLean E, Mardekian J, Cisar L, Hoang C, Harnett J
J Manag Care Spec Pharm
. 2016 Jul;
22(8):979-90.
PMID: 27459661
Background: Sunitinib and pazopanib are among the most prescribed targeted therapies for the systemic management of advanced renal cell carcinoma (RCC), but published cost comparisons between the 2 agents are...
2.
Parodi L, Pickering E, Cisar L, Lee D, Soufi-Mahjoubi R
Arch Drug Inf
. 2009 Jul;
1(3):97-106.
PMID: 19639031
PURPOSE: Statistical models for predicting hematologic toxicity were evaluated based on UGT1A1 polymorphisms and baseline serum bilirubin. METHODS: Blood DNA samples were collected from 113 patients with untreated metastatic colorectal...
3.
Schaaf L, Hammond L, Tipping S, Goldberg R, Goel R, Kuhn J, et al.
Clin Cancer Res
. 2006 Jun;
12(12):3782-91.
PMID: 16778106
Purpose: To determine the recommended starting doses and pharmacokinetics of irinotecan in cancer patients with impaired liver function treated on a weekly schedule. Experimental Design: Patients with solid tumors who...
4.
Rocha Lima C, Green M, Rotche R, Miller Jr W, Jeffrey G, Cisar L, et al.
J Clin Oncol
. 2004 Sep;
22(18):3776-83.
PMID: 15365074
Purpose: This phase III, randomized, open-label, multicenter study compared the overall survival associated with irinotecan plus gemcitabine (IRINOGEM) versus gemcitabine monotherapy (GEM) in patients with chemotherapy-naive, locally advanced or metastatic...